10-Q Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 Q3 2018

Filing Information

Form Type	10-Q
Accession Number	`0001493152-18-015756`
Period End Date	20180930
Filing Date	20181113
Fiscal Year	2018
Fiscal Period	Q3
XBRL Instance	ocx-20180930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 66 Income Statement 48 Cash Flow Statement 76 Comprehensive Income 16

Balance Sheet 66 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$10.17M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.60M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$11.02M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$10.82M	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$830.00K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$760.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$245.00K	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$168.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$11.90M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	85.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	85.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$8.53M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	31.45M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	40.66M	shares	Point-in-time
Intangible assets, net (Note 3)	`FiniteLivedIntangibleAssetsNet`	-	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	40.66M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	31.45M	shares	Point-in-time
Intangible assets, net (Note 3)	`FiniteLivedIntangibleAssetsNet`	$746.00K	USD	Point-in-time
Machinery and equipment, net	`PropertyPlantAndEquipmentNet`	$822.00K	USD	Point-in-time
Machinery and equipment, net	`PropertyPlantAndEquipmentNet`	$722.00K	USD	Point-in-time
Deposits and other noncurrent assets	`DepositsAndOtherNoncurrentAssets`	$287.00K	USD	Point-in-time
Deposits and other noncurrent assets	`DepositsAndOtherNoncurrentAssets`	$120.00K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$12.90M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$10.22M	USD	Point-in-time
Amount due to BioTime and affiliates	`DueToRelatedPartiesCurrent`	$2.10M	USD	Point-in-time
Amount due to BioTime and affiliates	`DueToRelatedPartiesCurrent`	$2.11M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$175.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$194.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$1.04M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$1.04M	USD	Point-in-time
Loan payable, current	`LoansPayableCurrent`	$800.00K	USD	Point-in-time
Loan payable, current	`LoansPayableCurrent`	$800.00K	USD	Point-in-time
Capital lease liability, current	`CapitalLeaseObligationsCurrent`	$338.00K	USD	Point-in-time
Capital lease liability, current	`CapitalLeaseObligationsCurrent`	$471.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.62M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.45M	USD	Point-in-time
Loan payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$531.00K	USD	Point-in-time
Loan payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$1.07M	USD	Point-in-time
Capital lease liability, noncurrent	`CapitalLeaseObligationsNoncurrent`	$289.00K	USD	Point-in-time
Capital lease liability, noncurrent	`CapitalLeaseObligationsNoncurrent`	$232.00K	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$5.38M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$5.81M	USD	Point-in-time
Commitments and contingencies (see Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (see Note 9)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 85,000 shares authorized; 40,664 and 31,452 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	`CommonStockValue`	$59.97M	USD	Point-in-time
Common stock, no par value, 85,000 shares authorized; 40,664 and 31,452 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	`CommonStockValue`	$74.34M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	-	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-888.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-66.82M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-54.68M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.52M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.40M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$12.90M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$10.22M	USD	Point-in-time

Income Statement 48 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$5.67M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$5.31M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.84M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.53M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$7.45M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$4.43M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$4.29M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.31M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$1.84M	USD	3 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$710.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$184.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$1.41M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$14.96M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$11.15M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$3.02M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$6.83M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-14.96M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-3.02M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-6.83M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-11.15M	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNet`	$-50.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-149.00K	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNet`	$-71.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-167.00K	USD	3 Qtrs
Unrealized gain on BioTime marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$102.00K	USD	1 Quarter
Unrealized gain on BioTime marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	3 Qtrs
Unrealized gain on BioTime marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	1 Quarter
Unrealized gain on BioTime marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$71.00K	USD	3 Qtrs
Loss on sale of available-for-sale securities and other expenses, net	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	$-309.00K	USD	3 Qtrs
Loss on sale of available-for-sale securities and other expenses, net	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	-	USD	1 Quarter
Loss on sale of available-for-sale securities and other expenses, net	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	$-3.00K	USD	3 Qtrs
Loss on sale of available-for-sale securities and other expenses, net	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	-	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$52.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-99.00K	USD	3 Qtrs
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-71.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-458.00K	USD	3 Qtrs
NET LOSS	`NetIncomeLoss`	$-15.41M	USD	3 Qtrs
NET LOSS	`NetIncomeLoss`	$-2.97M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-11.25M	USD	3 Qtrs
NET LOSS	`NetIncomeLoss`	$-6.91M	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.22	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.52	USD	3 Qtrs
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.30	USD	3 Qtrs
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.07	USD	1 Quarter
Weighted average common shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	29,775.00	shares	3 Qtrs
Weighted average common shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	36,901.00	shares	3 Qtrs
Weighted average common shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	30,941.00	shares	1 Quarter
Weighted average common shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	40,227.00	shares	1 Quarter

Cash Flow Statement 76 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-15.41M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-2.97M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-11.25M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-6.91M	USD	1 Quarter
Depreciation expense	`Depreciation`	$93.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$237.00K	USD	3 Qtrs
Depreciation expense	`Depreciation`	$317.00K	USD	3 Qtrs
Depreciation expense	`Depreciation`	$110.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$181.00K	USD	3 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$121.00K	USD	3 Qtrs
Amortization of prepaid maintenance	`AmortizationOfPrepaidMaintenance`	$9.00K	USD	3 Qtrs
Amortization of prepaid maintenance	`AmortizationOfPrepaidMaintenance`	-	USD	3 Qtrs
Impairment charge for intangible assets	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	3 Qtrs
Impairment charge for intangible assets	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$625.00K	USD	3 Qtrs
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$462.00K	USD	1 Quarter
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$1.08M	USD	3 Qtrs
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$345.00K	USD	1 Quarter
Stock-based compensation	`AllocatedShareBasedCompensationExpense`	$1.16M	USD	3 Qtrs
Loss on sale of BioTime shares	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	$-309.00K	USD	3 Qtrs
Loss on sale of BioTime shares	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	-	USD	1 Quarter
Loss on sale of BioTime shares	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	$-3.00K	USD	3 Qtrs
Loss on sale of BioTime shares	`AvailableForSaleSecuritiesGrossRealizedGainLossNet`	-	USD	1 Quarter
Unrealized gain on BioTime shares	`MarketableSecuritiesUnrealizedGainLoss`	$102.00K	USD	1 Quarter
Unrealized gain on BioTime shares	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	3 Qtrs
Unrealized gain on BioTime shares	`MarketableSecuritiesUnrealizedGainLoss`	-	USD	1 Quarter
Unrealized gain on BioTime shares	`MarketableSecuritiesUnrealizedGainLoss`	$71.00K	USD	3 Qtrs
Warrants issued to certain shareholders as inducement of exercise of warrants	`ProceedsFromIssuanceOfWarrants`	-	USD	3 Qtrs
Warrants issued to certain shareholders as inducement of exercise of warrants	`ProceedsFromIssuanceOfWarrants`	$4.07M	USD	3 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$62.00K	USD	3 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$57.00K	USD	3 Qtrs
Other	`OtherOperatingActivitiesCashFlowStatement`	-	USD	3 Qtrs
Other	`OtherOperatingActivitiesCashFlowStatement`	$23.00K	USD	3 Qtrs
Amount due to BioTime and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$12.00K	USD	3 Qtrs
Amount due to BioTime and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$-750.00K	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$119.00K	USD	3 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$77.00K	USD	3 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-39.00K	USD	3 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$227.00K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-9.19M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-10.04M	USD	3 Qtrs
Net proceeds from sale of BioTime shares	`ProceedsFromSaleOfAvailableForSaleSecuritiesEquity`	-	USD	3 Qtrs
Net proceeds from sale of BioTime shares	`ProceedsFromSaleOfAvailableForSaleSecuritiesEquity`	$934.00K	USD	3 Qtrs
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$85.00K	USD	3 Qtrs
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$31.00K	USD	3 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$849.00K	USD	3 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-31.00K	USD	3 Qtrs
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$465.00K	USD	3 Qtrs
Proceeds from exercise of options	`ProceedsFromStockOptionsExercised`	$58.00K	USD	3 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	3 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$7.77M	USD	3 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$10.00M	USD	3 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$65.00K	USD	3 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	-	USD	3 Qtrs
Proceeds from sale of common shares and warrants	`ProceedsFromSaleOfCommonSharesAndWarrants`	-	USD	3 Qtrs
Proceeds from sale of common shares and warrants	`ProceedsFromSaleOfCommonSharesAndWarrants`	$3.59M	USD	3 Qtrs
Financing costs to issue common shares and warrants	`FinancingCostsToIssueCommonSharesAndWarrants`	-	USD	3 Qtrs
Financing costs to issue common shares and warrants	`FinancingCostsToIssueCommonSharesAndWarrants`	$-290.00K	USD	3 Qtrs
Proceeds from issuance of loan payable, net of financing costs	`ProceedsFromDebtNetOfIssuanceCosts`	$1.98M	USD	3 Qtrs
Proceeds from issuance of loan payable, net of financing costs	`ProceedsFromDebtNetOfIssuanceCosts`	-	USD	3 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	$600.00K	USD	3 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	-	USD	3 Qtrs
Repayment of capital lease obligations	`RepaymentsOfLongTermCapitalLeaseObligations`	$179.00K	USD	3 Qtrs
Repayment of capital lease obligations	`RepaymentsOfLongTermCapitalLeaseObligations`	$250.00K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$10.04M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$12.45M	USD	3 Qtrs
NET INCREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$3.22M	USD	3 Qtrs
NET INCREASE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$850.00K	USD	3 Qtrs
At beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$10.17M	USD	Point-in-time
At beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$7.60M	USD	Point-in-time
At beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$11.02M	USD	Point-in-time
At beginning of the period	`CashAndCashEquivalentsAtCarryingValue`	$10.82M	USD	Point-in-time
At end of the period	`CashAndCashEquivalentsAtCarryingValue`	$10.17M	USD	Point-in-time
At end of the period	`CashAndCashEquivalentsAtCarryingValue`	$7.60M	USD	Point-in-time
At end of the period	`CashAndCashEquivalentsAtCarryingValue`	$11.02M	USD	Point-in-time
At end of the period	`CashAndCashEquivalentsAtCarryingValue`	$10.82M	USD	Point-in-time

Comprehensive Income 16 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-15.41M	USD	3 Qtrs
NET LOSS	`NetIncomeLoss`	$-2.97M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-11.25M	USD	3 Qtrs
NET LOSS	`NetIncomeLoss`	$-6.91M	USD	1 Quarter
Realized loss on sale of available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	3 Qtrs
Realized loss on sale of available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$293.00K	USD	3 Qtrs
Realized loss on sale of available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	1 Quarter
Realized loss on sale of available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	1 Quarter
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	-	USD	3 Qtrs
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	-	USD	1 Quarter
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-110.00K	USD	1 Quarter
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-284.00K	USD	3 Qtrs
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-15.41M	USD	3 Qtrs
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-2.97M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-7.02M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-11.25M	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.